6 results on '"Rodriguez-Otero P."'
Number of results to display per page
Search Results
2. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
- Author
-
Mateos, Maria-Victoria, Weisel, Katja, De Stefano, Valerio, Goldschmidt, Hartmut, Delforge, Michel, Mohty, Mohamad, Cavo, Michele, Vij, Ravi, Lindsey-Hill, Joanne, Dytfeld, Dominik, Angelucci, Emanuele, Perrot, Aurore, Benjamin, Reuben, van de Donk, Niels W. C. J., Ocio, Enrique M., Scheid, Christof, Gay, Francesca, Roeloffzen, Wilfried, Rodriguez-Otero, Paula, Broijl, Annemiek, Potamianou, Anna, Sakabedoyan, Caline, Semerjian, Maria, Keim, Sofia, Strulev, Vadim, Schecter, Jordan M., Vogel, Martin, Wapenaar, Robert, Nesheiwat, Tonia, San-Miguel, Jesus, Sonneveld, Pieter, Einsele, Hermann, and Moreau, Philippe
- Published
- 2022
- Full Text
- View/download PDF
3. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
- Author
-
Facon, Thierry, Dimopoulos, Meletios A., Meuleman, Nathalie, Belch, Andrew, Mohty, Mohamad, Chen, Wen-Ming, Kim, Kihyun, Zamagni, Elena, Rodriguez-Otero, Paula, Renwick, William, Rose, Christian, Tempescul, Adrian, Boyle, Eileen, Manier, Salomon, Attal, Michel, Moreau, Philippe, Macro, Margaret, Leleu, Xavier, Lorraine Chretien, Marie, Ludwig, Heinz, Guo, Shien, Sturniolo, Michael, Tinel, Antoine, Silvia Monzini, Mara, Costa, Bruno, Houck, Vanessa, Hulin, Cyrille, and Yves Mary, Jean
- Published
- 2020
- Full Text
- View/download PDF
4. Defining and treating high-risk multiple myeloma
- Author
-
Usmani, S Z, Rodriguez-Otero, P, Bhutani, M, Mateos, M-V, and Miguel, J S
- Published
- 2015
- Full Text
- View/download PDF
5. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma
- Author
-
Garcés, Juan-José, Bretones, Gabriel, Burgos, Leire, Valdes-Mas, Rafael, Puig, Noemi, Cedena, Maria-Teresa, Alignani, Diego, Rodriguez, Idoia, Puente, Diana Álvarez, Álvarez, Miguel-García, Goicoechea, Ibai, Rodriguez, Sara, Calasanz, Maria-Jose, Agirre, Xabier, Flores-Montero, Juan, Sanoja-Flores, Luzalba, Rodriguez-Otero, Paula, Rios, Rafael, Martinez-Lopez, Joaquin, Millacoy, Pamela, Palomera, Luis, Del Orbe, Rafael, Pérez-Montaña, Albert, El Omri, Halima, Prosper, Felipe, Mateos, Maria-Victoria, Rosiñol, Laura, Blade, Joan, Lahuerta, Juan-Jose, Orfao, Alberto, Lopez-Otin, Carlos, San Miguel, Jesus F., and Paiva, Bruno
- Abstract
Multiple myeloma (MM) patients undergo repetitive bone marrow (BM) aspirates for genetic characterization. Circulating tumor cells (CTCs) are detectable in peripheral blood (PB) of virtually all MM cases and are prognostic, but their applicability for noninvasive screening has been poorly investigated. Here, we used next-generation flow (NGF) cytometry to isolate matched CTCs and BM tumor cells from 53 patients and compared their genetic profile. In eight cases, tumor cells from extramedullary (EM) plasmacytomas were also sorted and whole-exome sequencing was performed in the three spatially distributed tumor samples. CTCs were detectable by NGF in the PB of all patients with MM. Based on the cancer cell fraction of clonal and subclonal mutations, we found that ~22% of CTCs egressed from a BM (or EM) site distant from the matched BM aspirate. Concordance between BM tumor cells and CTCs was high for chromosome arm-level copy number alterations (≥95%) though not for translocations (39%). All high-risk genetic abnormalities except one t(4;14) were detected in CTCs whenever present in BM tumor cells. Noteworthy, ≥82% mutations present in BM and EM clones were detectable in CTCs. Altogether, these results support CTCs for noninvasive risk-stratification of MM patients based on their numbers and genetic profile.
- Published
- 2020
- Full Text
- View/download PDF
6. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
- Author
-
Margaret Macro, Andrew Ar Belch, Antoine Tinel, Nathalie Meuleman, Jean Yves Mary, Christian Rose, Paula Rodriguez-Otero, Philippe Moreau, Wenming Chen, Michel Attal, Marie Lorraine Chretien, William Renwick, Kihyun Kim, Meletios A. Dimopoulos, Eileen M Boyle, Xavier Leleu, Michael Sturniolo, Thierry Facon, Heinz Ludwig, Mara Silvia Monzini, Vanessa Houck, Elena Zamagni, Adrian Tempescul, Salomon Manier, Cyrille Hulin, Shien Guo, Mohamad Mohty, Bruno M. Costa, Facon T., Dimopoulos M.A., Meuleman N., Belch A., Mohty M., Chen W.-M., Kim K., Zamagni E., Rodriguez-Otero P., Renwick W., Rose C., Tempescul A., Boyle E., Manier S., Attal M., Moreau P., Macro M., Leleu X., Lorraine Chretien M., Ludwig H., Guo S., Sturniolo M., Tinel A., Silvia Monzini M., Costa B., Houck V., Hulin C., Yves Mary J., CIC CHU ( Lille)/inserm, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé, National and Kapodistrian University of Athens (NKUA), Institut Jules Bordet [Bruxelles], Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Cross Cancer Institute [Edmonton, AB, Canada], Service d'immunologie et hématologies biologiques [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Capital Medical University, Beijing, Samsung Medical Center Sungkyunkwan University School of Medicine, Institute Division of Hematology/Oncology, Azienda Ospedaliero-Universitaria, Universidad de Navarra [Pamplona] (UNAV), Western Health The University of Melbourne, Université catholique de Lille (UCL), CHRU Brest - Service d'Hématologie (CHU-Brest-Hemato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Hôtel-Dieu de Nantes - Centre Hospitalier Universitaire de Nantes (Hôpital Hôtel-Dieu de Nantes - CHU de Nantes), Hôpital Universitaire de Caen, Hôpital de la Milétrie, Centre hospitalier universitaire de Poitiers (CHU Poitiers), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Wilhelminenspital Vienna, Evidera, Celgene Corporation, Celgene International, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Michel, Geneviève, Lymphocytes B, Autoimmunité et Immunothérapies (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Institut Brestois Santé Agro Matière (IBSAM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Wilhelminenspital Vienna = Wilhelminen Hospital
- Subjects
0301 basic medicine ,Male ,Cancer Research ,[SDV]Life Sciences [q-bio] ,Dexamethasone ,0302 clinical medicine ,Clinical trials ,Multiple myeloma ,Antineoplastic Combined Chemotherapy Protocols ,Stage (cooking) ,Lenalidomide ,Melphalan ,Aged, 80 and over ,Frailty ,Hematology ,Middle Aged ,3. Good health ,Thalidomide ,[SDV] Life Sciences [q-bio] ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Female ,Multiple Myeloma ,Haematological diseases ,Human ,Adult ,medicine.medical_specialty ,FIRST (MM-020) trial ,Frail Elderly ,Newly diagnosed ,Transplant ineligible ,Anesthésiologie ,Article ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,In patient ,Adverse effect ,Aged ,Antineoplastic Combined Chemotherapy Protocol ,business.industry ,medicine.disease ,Clinical trial ,Cancérologie ,030104 developmental biology ,Charlson comorbidity index ,Prednisone ,business ,Hématologie - Abstract
Patients with multiple myeloma are generally older and vary in fitness levels, which may influence the clinical benefit of treatment. Patients from the large, phase 3 FIRST trial in newly diagnosed multiple myeloma (NDMM) were retrospectively investigated to determine outcomes based on frailty using scores for age, Charlson Comorbidity Index (CCI), and Eastern Cooperative Oncology Group performance status (ECOG PS), instead of the EQ-5D quality-of-life questionnaire, as previously reported. ECOG PS (n = 1618) was investigated in frailty groups: frail (49%) and nonfrail (51%). Frail patients experienced worse progression-free and overall survival vs nonfrail patients. Prognostic assessment was improved when combining frailty and International Staging System stage (I/II vs III). Frail patients had a higher risk of developing grade 3/4 treatment-emergent adverse events. Treatment effects observed in the FIRST trial were confirmed per frailty group and per frailty and ISS group. The use of this ECOG PS–containing frailty scale as a predictive measure of clinical outcomes in patients with transplant-ineligible NDMM is supported by data from the FIRST trial. This score, based on age, CCI, and ECOG PS, can be easily replicated and may help design future myeloma studies in frail or nonfrail elderly patients., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2019
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.